The Gilbert Group is currently interested in research centered on the statistical design and analysis of HIV vaccine efficacy trials, with emphasis on assessing immune correlates of vaccine-induced protection including the “sieve analysis” of the HIV sequences infecting trial volunteers. While being motivated by HIV vaccine efficacy trials, this research contributes to general areas of statistical methods research including surrogate endpoint assessment, causal inference, survival analysis, and efficient randomized trial design. In collaboration with scientists from the Thai Ministry of Health and the United States Military HIV Research Program, Peter led the statistical design and analysis of an immune correlates study of the RV144 “Thai Trial” (published in 2012), which established a process for correlates discovery that may be useful for other vaccine trial settings. In addition, Peter led the statistical design of a sequential Phase 2b trial design for evaluating vaccine efficacy and immune correlates for multiple HIV vaccine regimens (published in 2011), which is planned for implementation and may be useful for other vaccine trial settings.
1997: Postdoctoral fellow, Department of Biostatistics, Harvard School of Public Health
1998 - 2001: Assistant Professor, Department of Biostatistics, Harvard School of Public Health
2001 - present: Faculty member, Vaccine and Infectious Disease and Public Health Sciences Divisions, FHCRC
2001 - present: Faculty member, Department of Biostatistics, University of Washington
2005 - 2006: Ross L. Prentice Professor, Department of Biostatistics, University of Washington
2013 – present: Director, Biostatistics, Bioinformatics and Epidemiology, Vaccine and Infectious Disease Division